115 related articles for article (PubMed ID: 37665683)
1. A phase-I randomized euglycemic clamp study to demonstrate the pharmacokinetic and pharmacodynamic equivalence of an insulin degludec biosimilar (B01411) with the reference product in healthy Chinese volunteers.
Liu H; Li T; Yu H; Chen X; Li J; Tan H; Jia D; Yu Y
Expert Opin Investig Drugs; 2023; 32(8):773-781. PubMed ID: 37665683
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
[TBL] [Abstract][Full Text] [Related]
4. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I
Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248
[No Abstract] [Full Text] [Related]
5. Similar pharmacokinetics and pharmacodynamics of a new biosimilar and reference insulin aspart in healthy Chinese males.
Liu H; Yu H; Sun L; Qiao J; Wan S; Li S; Li J; Tan H; Yu Y
Sci Rep; 2021 May; 11(1):9495. PubMed ID: 33947913
[TBL] [Abstract][Full Text] [Related]
6. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Andersen G; Singh G; Murugesan SMN; Gogineni R; Sharma N; Panda J; Marwah A; Loganathan S; Athalye SN
Diabetes Obes Metab; 2023 Jun; 25(6):1485-1494. PubMed ID: 36708333
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: A randomized, double-blind, crossover, euglycaemic glucose clamp study.
Hövelmann U; Raiter Y; Chullikana A; Liu M; Donnelly C; Lawrence T; Sengupta N; Cl G; Ranganna G; Barve A
Diabetes Obes Metab; 2021 Dec; 23(12):2670-2678. PubMed ID: 34378861
[TBL] [Abstract][Full Text] [Related]
9. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Haahr H; Sasaki T; Bardtrum L; Ikushima I
J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
[TBL] [Abstract][Full Text] [Related]
10. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.
Heise T; Nosek L; Bøttcher SG; Hastrup H; Haahr H
Diabetes Obes Metab; 2012 Oct; 14(10):944-50. PubMed ID: 22726241
[TBL] [Abstract][Full Text] [Related]
11. The Effect of BMI on Pharmacokinetic and Pharmacodynamic Parameters of Insulin Degludec: Results from an Euglycemic Glucose Clamp Study.
Li T; Liu H; Li S; Yu H; Li J; Tan H; Yu Y
Clin Pharmacokinet; 2023 Mar; 62(3):449-456. PubMed ID: 36738401
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus
Bhatia A; Tawade S; Mastim M; Kitabi EN; Gopalakrishnan M; Shah M; Yeshamaina S; Gobburu J; Sahib M; Thakur D; Prasanna Kumar KM
Acta Diabetol; 2018 May; 55(5):461-468. PubMed ID: 29453671
[TBL] [Abstract][Full Text] [Related]
13. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Korsatko S; Deller S; Mader JK; Glettler K; Koehler G; Treiber G; Urschitz M; Wolf M; Hastrup H; Søndergaard F; Haahr H; Pieber TR
Drugs Aging; 2014 Jan; 31(1):47-53. PubMed ID: 24263619
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
Ikushima I; Kaku K; Hirao K; Bardtrum L; Haahr H
J Diabetes Investig; 2016 Mar; 7(2):270-5. PubMed ID: 27042281
[TBL] [Abstract][Full Text] [Related]
15. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects.
Shiramoto M; Yoshihara T; Schmider W; Takagi H; Nowotny I; Kajiwara M; Muto H
Sci Rep; 2021 Nov; 11(1):22931. PubMed ID: 34824344
[TBL] [Abstract][Full Text] [Related]
17. Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan-Approved Humalog Insulin Lispro in Healthy Japanese Subjects.
Shiramoto M; Yoshihara T; Schmider W; Takahashi Y; Nowotny I; Kajiwara M; Muto H
Clin Pharmacol Drug Dev; 2022 Jun; 11(6):754-760. PubMed ID: 35166054
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.
Korsatko S; Deller S; Koehler G; Mader JK; Neubauer K; Adrian CL; Thomsen H; Haahr H; Pieber TR
Clin Drug Investig; 2013 Jul; 33(7):515-21. PubMed ID: 23749405
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure.
Drai RV; Karonova TL; Mayorov AY; Makarenko IE; Dorotenko AR; Kulesh VS; Kovalik VV; Andreeva AT
Clin Pharmacol Drug Dev; 2022 Aug; 11(8):922-929. PubMed ID: 35230749
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus
Wang Y; Zhou Y; Ding J; Li X; Guo F; Zhang J; Ding L
Front Pharmacol; 2022; 13():962201. PubMed ID: 36091767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
